RCS - PureTech Health PLC - PRTC's Seaport Adds Microsoft and J&J Exec to BOD

Puretech HealthAnnouncement

20/11/2024 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241120:nRST8957Ma&default-theme=true

RNS Number : 8957M  PureTech Health PLC  20 November 2024

20 November 2024

PureTech Health plc

 

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board
of Directors

 

Lead Independent Director at Microsoft and former Group Worldwide Chair for
Johnson & Johnson brings extensive experience in life sciences innovation,
governance and operations

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted
that its Founded Entity, Seaport Therapeutics (https://seaporttx.com/) ,
("Seaport") a biopharmaceutical company that is advancing novel
neuropsychiatric medicines with a proven strategy and team, today announced
that Sandra (Sandi) Peterson has been appointed to its Board of Directors. Ms.
Peterson is a prominent and seasoned business leader with extensive experience
driving innovation and operational excellence across leading global life
sciences and consumer organizations.

 

The full text of the announcement from Seaport is as follows:

 

Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

 

Lead Independent Director at Microsoft and former Group Worldwide Chair for
Johnson & Johnson brings extensive experience in life sciences innovation,
governance and operations

 

BOSTON, November 20, 2024 - Seaport Therapeutics (https://seaporttx.com/)
("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that
is advancing novel neuropsychiatric medicines with a proven strategy and team,
today announced that Sandra (Sandi) Peterson has been appointed to its Board
of Directors. Ms. Peterson is a prominent and seasoned business leader with
extensive experience driving innovation and operational excellence across
leading global life sciences and consumer organizations.

 

Ms. Peterson has held a series of high-profile leadership roles over the
course of her career. Currently, she is an Operating Partner at Clayton,
Dubilier & Rice, (CD&R), a private investment firm, where she invests
in life sciences and consumer companies and oversees technology initiatives to
enhance performance of the firm's portfolio companies. Prior to joining
CD&R in 2019, Ms. Peterson was Group Worldwide Chair for Johnson &
Johnson (J&J), where she led the company's consumer and medical devices
businesses and was responsible for global operating infrastructure,
technology, supply chain, quality and key strategic initiatives.

 

"Sandi has garnered a wealth of experience over the course of her impressive
career that will be a tremendous asset to Seaport as we advance novel
neuropsychiatric medicines for patients and their families," said Daphne
Zohar, Founder and Chief Executive Officer of Seaport Therapeutics. "We are
fortunate to have excellent individuals on our Board of Directors who each
contribute unique expertise, and Sandi's proven ability to drive innovation
and scale global businesses will be particularly meaningful as we accelerate
development of our pipeline."

 

Previously, Ms. Peterson served as Chairman & CEO of Bayer CropScience AG,
CEO of Bayer Medical Care, and President of Bayer HealthCare AG's Diabetes
Care Division. She held executive positions at Medco Health Solutions
(formerly known as Merck-Medco), Nabisco, Whirlpool and McKinsey. In addition
to her Board position at Seaport, Ms. Peterson serves on the Microsoft Board
of Directors as the lead independent director; Executive Chairwoman of
Volastra Therapeutics; Board Chair of the American Academy in Berlin and
Executive Committee Member of the Institute for Advanced Study.

 

"Seaport's innovative approach to developing new medicines for
neuropsychiatric conditions has the potential to radically transform the
treatment landscape for patients, particularly for those suffering from
depression and anxiety," said Ms. Peterson. "I look forward to working with
Seaport's excellent leadership team and Board to drive forward our commitment
to improve patient outcomes through science and innovation."

 

Ms. Peterson has appeared on Fortune Magazine's list of Most Powerful Women in
Business numerous times and was featured on the magazine's inaugural list of
Leaders Who Are Changing Healthcare. She received her B.A. from Cornell
University and her M.P.A. from Princeton University.

 

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing
the development of novel neuropsychiatric medicines in areas of high unmet
patient needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are overcome
with its proprietary Glyph technology platform. All the therapeutic
candidates in its pipeline of first and best-in-class medicines are based on
the Glyph platform, which is uniquely designed to enable oral bioavailability,
bypass first-pass metabolism and reduce liver enzyme elevations or
hepatotoxicity and other side effects. Seaport is led by an experienced team
that invented and advanced important neuropsychiatric medicines and are guided
by an extensive network of renowned scientists, clinicians and key opinion
leaders. For more information, please visit www.seaporttx.com
(http://www.seaporttx.com/) .

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of therapeutic
candidates were initially identified or discovered and then advanced by the
PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com) or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to Seaport's development plans for
its pipeline of therapeutics for the treatment of depression, anxiety and
other neuropsychiatric disorders, potential benefits to patients, and
Seaport's and our future prospects, developments and strategies. The
forward-looking statements are based on current expectations and are subject
to known and unknown risks, uncertainties and other important factors that
could cause actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the caption "Risk
Factors" in our Annual Report on Form 20-F for the year ended December 31,
2023, filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com (mailto:jchen@tenbridgecommunications.com)
 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPGUWGUPCUGU